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Editorial: ‘cMyC - how a novel biomarker could transform chest pain triage’ 1 
Chest pain is a common symptom – according to recent literature it is responsible for at least 6% of 2 
all presentations to emergency departments – however, only about 10% of these patients have a 3 
final diagnosis of Acute Myocardial Infarction (AMI).[1–5] Chest pain triage is fraught with 4 
difficulties as physicians are increasingly caught at the interplay of sensitivity and specificity: 5 
Fewer patients now have the diagnostic electrocardiogram (ECG) changes of ST-elevation or 6 
depression that allow triage at presentation [6,7] – in fact, 68% of all patients eventually diagnosed 7 
with an acute coronary syndrome (ACS) present with Non-ST elevation myocardial infarction 8 
(NSTEMI).[8] Consequently, triage has become reliant on the elevation in the blood of the 9 
biomarker cardiac Troponin (cTn). This is enshrined in the Universal Definition of Myocardial 10 
Infarction [9] and guidelines published by the European Society of Cardiology (ESC) [10], 11 
mandating the detection of a cardiac biomarker rise and/or fall for the diagnosis of AMI. 12 
The challenging reality of chest pain triage 13 
The technological advances in evolving cTn assays to high-sensitivity tests comes at the expense of 14 
loss of specificity; as analysers are increasingly able to provide quantifiable cTn levels in almost 15 
every individual.[11,12] The very definition of a hs-cTn assay – according to the International 16 
Federation of Clinical Chemistry and Laboratory Medicine Task Force on Clinical Applications of 17 
cardiac Bio-Markers (IFCC TF-CB) – includes 1) a Coefficient of Variation (CV) ≤10% at the 99th 18 
centile value and 2) the ability to measure at least 50% of healthy individuals with concentrations 19 
above the assay’s Limit of Detection (LoD).[13,14] The clinical reality of this advance in assay-20 
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technology is that many more patients test ‘Troponin-positive’, but not necessarily ‘AMI-positive’ – 1 
all in an attempt to overcome the limitations which made cTn inherently unsuited for early 2 
diagnosis of acute myocardial injury: a slow rise and disappearance from the blood stream after 3 
myocardial injury.[15,16] By the ESC’s own admission, the clinical implications of using high-4 
sensitivity (hs) cTn assays include a 2-fold increase of detection of type 2 AMI, ~20% relative 5 
increase in detection of type 1 AMI and ‘elevations up to 3-fold the upper reference limit 6 
(URL)…may be associated with a broad spectrum of conditions’. 7 
Sensitivity comes at a cost 8 
The emergency physician is caught up in this sensitivity/specificity quagmire: they have to handle 9 
complex rule-in/rule-out algorithms to optimise care for the patient with suspected Acute Coronary 10 
Syndrome (ACS) at the front-door of the hospital.[10,17] Two aspects make this inherently more 11 
challenging: 1) Even with high-sensitivity assays, the ESC advocates a delay of 3 hours after chest 12 
pain onset for the first blood draw to take place; 2) Many patients get caught up in an ‘observe’ 13 
zone of indeterminate risk – too high a cTn level for discharge, but too low to classify as AMI. 14 
Without doubt, evermore-sensitive assays will establish a new reality of biomarker-interpretation in 15 
acute medical services around the world – the (nearly) always-quantifiable level of a cardiac 16 
biomarker ought to be scrutinised in the context of the clinical presentation, and we can no longer 17 
rely on an outdated black & white approach. But maybe we can achieve more effective triage using 18 
a highly-sensitive and specific biomarker with a more favourable release profile? 19 
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There might be another way… 1 
Cardiac myosin-binding protein C (cMyC) is a promising novel biomarker of myocardial injury – 2 
originally described as the C-protein by Offer et al. in 1973 [18], its discovery relied on the 3 
characterisation of ‘impurities’ detected alongside myosin. cMyC has distinctive release-kinetics 4 
that should enable it to act as a better adjudicator of acute versus chronic myocardial injury than 5 
Troponin.[19] We have raised monoclonal antibodies targeting the cardiac isoform of myosin-6 
binding protein C and successfully migrated the assay onto a high-sensitivity platform.[12] 7 
Subsequently, we demonstrated up to 10-fold greater abundance of cMyC after myocardial injury 8 
than two leading hs-cTnT/I assays.[20] In a small study involving 174 patients presenting within 3 9 
hours of chest pain onset and suspected AMI, we demonstrated a more dynamic rise of cMyC in the 10 
early stages of AMI than hs-cTnI.[21] This faster rise ought to yield a positive result (for rule-in of 11 
AMI), or an earlier reliable negative result (for rule-out of AMI). Furthermore, the relative 12 
abundance of cMyC should allow careful calibration of rule-out and rule-in thresholds, with more 13 
‘headroom’ to enable precise quantification at the low concentrations needed for rule-out. 14 
Large chest pain study confirms efficacy 15 
This hypothesis was tested in a study of >1,900 patients with symptoms suggestive of AMI – in an 16 
internal derivation/validation split, we derived cut-off thresholds for immediate rule-out or rule-in 17 
of AMI using cMyC instead of hs-cTnT/I (modelled on the 2015 ESC NSTEMI guideline).[10,22] 18 
At similar diagnostic accuracy (based on comparable area under the receiver-operating 19 
characteristics curve), cMyC was substantially more effective than either hs-cTn assay in guiding 20 
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patients to (safe) rule-out or rule-in: the net reclassification improvement demonstrated 14.9-23.5% 1 
better triage efficiency, thus reducing the size of the ‘observe’ zone substantially. Based on an 2 
institution such as St Thomas’ Hospital, a central London hospital home to a tertiary cardiac unit, 3 
about 7,800 patients are subject to hs-cTnT testing in the Emergency Department annually. [23] Our 4 
findings would translate into savings of 1,000 bed days per year – simply by achieving a more 5 
effective triage with a single blood draw at presentation.  6 
Faster, better…Point-of-Care? 7 
But, there is an even greater goal to aim for: point-of-care testing (POCT) of cardiac biomarkers. To 8 
date, there is no POCT device that can achieve the levels of sensitivity required to provide accurate 9 
measurement of troponin for rule-out of AMI. This task requires a POCT assay to achieve a limit of 10 
detection equivalent to the laboratory assay, as the ESC guidelines advocate rule-out only in 11 
patients with undetectable hs-cTn levels. The best cTnT POCT platform (Roche Cobas h323 12 
handheld instrument) can detect a laboratory-equivalent value of 50 ng/L – about 3.5-fold greater 13 
than the 99th centile, or 10-fold the LoD of the laboratory assay.[24] While not bioequivalent, it is 14 
tempting to speculate whether cMyC – with a 10-fold greater abundance, and a rule-out threshold 15 
25-fold the LoD of the current laboratory platform – might facilitate easier migration onto a 16 
handheld device. This would allow rapid deployment of a novel cardiac biomarker to secondary and 17 
tertiary care facilities, and pave the way to a cluster-randomised controlled trial. Such a trial, with 18 
ethical consent at institutional level to ensure rapid enrolment of a large number of participants, 19 
would allow – for the first time – a head-to-head comparison of the effectiveness of different 20 
cardiac biomarkers in acute chest pain triage. The potential advantages are compelling: as most 21 
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patients presenting with chest pain do not have AMI, the goal must be to rule-out AMI in as many 1 
patients as possible at the earliest opportunity – i.e. with the first blood draw. Even better, if this 2 
could be facilitated in a pre-hospital setting, where cMyC seems to benefit from dynamic release 3 
kinetics.[25] cMyC might allow earlier rule-out of AMI [22], and if the promise of more effective 4 
triage holds true, up to a fifth of all patients could benefit from expedited discharge, or care where 5 
necessary. 6 
In conclusion, cMyC is a cardiac-restricted protein which rapidly enters the systemic circulation 7 
after myocardial injury and is relatively more abundant than troponin. The biomarker performs 8 
favourably in the diagnosis of AMI and is particularly well-suited to a point-of-care diagnostic 9 
platform – which could transform the way we perform chest pain triage. 10 
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